Shuttle Pharmaceuticals
SHPH
6 hedge funds and large institutions have $513K invested in Shuttle Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
2,930% more capital invested
Capital invested by funds: $16.9K → $513K (+$496K)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more funds holding
Funds holding: 3 → 6 (+3)
1.31% more ownership
Funds ownership: 0.04% → 1.35% (+1.3%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$376K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$160K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.37K |
| 4 |
Morgan Stanley
New York
|
+$112 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$37 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
-$3.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
1
Connective Capital Management
Palo Alto,
California
| $357K | +$376K | +10,054 | New |
|
|
DS
2
DRW Securities
Chicago,
Illinois
| $152K | +$160K | +4,283 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3.6K | +$3.37K | +90 | +750% |
|
|
4
Morgan Stanley
New York
| $96 | +$112 | +3 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $28 | -$12.6K | -336 | -100% |
|
|
6
Bank of America
Charlotte,
North Carolina
| $28 | +$37 | +1 | New |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $7 | – | – | – |
|
|
8
Raymond James Financial
St Petersburg,
Florida
| – | -$3.77K | -100 | Closed |
|
SHPH Hedge Fund Activity: Q3 2025 in Review
6 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q3 2025, worth a combined $513K — up 2,930% from $16.9K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SHPH positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $376K. The largest seller was UBS Group, cutting an estimated $12.6K.
- 6 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q3 2025, up from 3 in Q2 2025.
- Funds reported $513K of Shuttle Pharmaceuticals stock for Q3 2025, up 2,930% quarter-over-quarter.
- 4 funds opened new Shuttle Pharmaceuticals positions in Q3 2025 and 1 closed out, a net change of +3 holders.
- The largest Shuttle Pharmaceuticals buyer in Q3 2025 was Connective Capital Management, an estimated $376K added.
- The largest Shuttle Pharmaceuticals seller in Q3 2025 was UBS Group, an estimated $12.6K sold.
Based on aggregated 13F filings for Q3 2025.